Navigation Links
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Date:5/30/2009

Clinical Data Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida.

Dr. E. Gabriela Chiorean, from the Indiana University Simon Cancer Center in Indianapolis, IN presented the interim Phase I data on SF1126 in 36 advanced solid tumor patients. The majority of patients were heavily pretreated with a median of four prior chemotherapy regimens. Sixteen of 36 (44%) patients achieved disease stabilization with a median duration of 12 weeks. Of note, a GIST, endometrial, and prostate cancer patient each achieved durable stable disease for 20 weeks (5 mos.). These specific tumor types are associated with aberrations of the PI3K pathway that commonly lead to resistance and poor prognostic outcomes.

Pharmacodynamic analysis of tumor tissue confirmed inhibition of the PI3K pathway by complete absence of a downstream target (pS6). In contrast, a normal tissue (skin) demonstrated no inhibition providing evidence of tumor selectivity of SF1126. Pharmacokinetics displayed dose proportionality and no accumulation between cycles.

SF1126 was well tolerated. The most common side effects were grade 1 or 2 vomiting (42%), nausea (39%), diarrhea (33%), fever (22%), fatigue (19%), chills (14%), and puritis (11%). There were two patients with grade 3 toxicity, one with diarrhea, the other with urticaria and pruritis. Notably, there were no clinically significant changes in glucose or insulin levels reported.

"Based on these Phase I results we are encouraged that SF1126 is well tolerated and may hold promise for the treatment of solid tumor maligna
'/>"/>

SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
3. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
4. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
7. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
8. Cardiologists Tackle Next Frontier in Cardiovascular Disease
9. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 The U.S. Food and Drug ... been added to the label for the HIV ... effects on the heart when used with Norvir ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
... 21 Span-America Medical Systems, Inc. (Nasdaq:  SPAN) will ... conference call on Tuesday, November 2, 2010, covering results ... be released after the regular close of trading the ... conference call will be available online at  www.spanamerica.com ...
Cached Medicine Technology:New Label Changes for Commonly Prescribed HIV Drug Invirase 2
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Feb. 20 When Avaya rolls its,18-wheel ... floor of HIMSS08,next week, onboard will be ... are helping healthcare organizations address critical,communications challenges ... a leading global provider of business communications ...
... announced that, due to continuing declines in Portamedic revenues,the ... fourth quarter 2007,excluding the gain on sale of its ... to a greater than expected,reduction in paramedical exams of ... year. Regarding 2008, the Company no longer expects to ...
... MacuSight(TM), Inc., a,developer of innovative therapeutics for ... announced the appointment of Joel Naor,M.D., M.Sc., MBA, ... in the clinical development of therapeutics for ocular ... role in MacuSight,s ongoing,advancement of its sirolimus program, ...
... Feb. 20 IDM Pharma, Inc.,(Nasdaq: IDMI ) ... Market that the Company has regained compliance with NASDAQ,Marketplace ... bid price of at least $1.00 per share., ... Company,s common stock,was $3.14 per share., About IDM ...
... Featured At Premier Las Vegas Training Facility, ... global,leader in dental and aesthetic lasers, today announced ... Dental Studies (LVI), an,internationally recognized leader in post-graduate ... lasers will be utilized at,LVI,s state-of-the-art teaching facility ...
... finds anxiety over financial, preparedness; consumers say health care ... ... WASHINGTON, Feb. 20 American consumers want more from,their health ... care providers and medical records, customized,insurance coverage and wider access to ...
Cached Medicine News:Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 3Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 4Health News:Hooper Holmes Updates Guidance 2Health News:Hooper Holmes Updates Guidance 3Health News:MacuSight Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer 2Health News:IDM Pharma Announces Compliance With NASDAQ Minimum Bid Price Requirements 2Health News:HOYA ConBio Announces Educational Agreement With LVI Global 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 2Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 3Health News:Groundbreaking Deloitte Survey Reveals Many U.S. Consumers Want Major Changes in Health Care Design, Delivery 4
... These corrosion proof polypropylene exhaust hoods ... edge of tanks and draw a stream ... tank away from the operator. Other sizes ... semi-canopy, lateral, and double-slot are available on ...
These handy dispensers save space and organize gloves in labs and next to hand washers. Static-dissipative PVC eliminates static charges and the particles they attract . Many other sizes and custom c...
... base sliding microtome offers the ultimate in ... not least, safety. ,Designed to meet the ... 8000 will also meet the more demanding ... versatility and wide range of accessories will ...
... Starter Package is a solid ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a rotating stage assembly for ...
Medicine Products: